The Latest Breaking News from NVS

With the persistent rise in lifestyle diseases, the pharmaceutical industry is well poised for strong growth in the long term. Also, with the Fed likely to keep increasing the interest rates, the economy is likely to enter a recession, making pharma stocks attractive investment options. Therefore, investors could look to…

Due to a barrage of strong macroeconomic data, the Federal Reserve has expressed the need to keep interest rates elevated. This is expected to keep the market volatile. Amid this backdrop, it might be wise to buy fundamentally strong dividend stocks Johnson & Johnson (JNJ), Novartis (NVS), and ARC Document…

The pharma industry witnessed solid growth amid the pandemic. Moreover, with surging demand, rising investments in research and development, and increasing e-pharmacy channels, the industry is well-positioned for significant growth over the coming years. Therefore, investors could consider buying fundamentally sound pharma stocks Johnson & Johnson (JNJ), AbbVie (ABBV), and…

Despite eased inflation, the robust jobs report raised the prospect of progressive rate hikes. With anxiety escalating about the possibility of a Fed-induced recession, the market volatility is expected to remain elevated in the near future. Hence, investors could consider fundamentally sound and stable stocks Novartis (NVS), Descartes Systems (DSGX),…

The stock market witnessed a solid start this year amid improving investors’ optimism. Moreover, experts see increased chances of a soft landing. So, fundamentally strong stocks Merck (MRK), Novartis (NVS), Sysco (SYY), Progress Software (PRGS), and LSI Industries (LYTS) could be solid buys now. These stocks pay consistent dividends. Read…

Despite the recent positive macro data, the recession possibility remains as the Federal Reserve is expected to keep hiking rates until its target is met. So, dividend-paying healthcare stocks Novartis (NVS) and Takeda Pharmaceutical (TAK) could be stable investment options to safeguard your portfolios. These stocks are trading under $100.…

The stock market witnessed a decent rally in January, with cooling inflationary pressures reducing recession fears. However, the Fed’s attempts to bring inflation down to its 2% target could hurt economic growth. Hence, it could be wise to invest in shares of Johnson & Johnson (JNJ), Novartis (NVS), and LCNB…

Although headline inflation has slowed, the Fed will likely keep raising interest rates to attain its 2% target. However, a potential slowdown in monetary policy tightening is opening the path for quality stocks to recover. Therefore, investors should consider buying fundamentally sound stocks Merck & Co. (MRK), Novartis (NVS), and…

The Fed’s intention to continue raising interest rates, disappointing economic data, and a weak earnings season could keep the stock market highly volatile. Hence, investing in quality stocks Microsoft (MSFT), Johnson (JNJ), and Novartis (NVS) could be safe. Continue reading.